|
|
|
|
|
Silva,Nanci; Oliveira,Márcio; Bandeira,Antonio Carlos; Brites,Carlos. |
Nosocomial infection caused by extended-spectrum beta-lactamase producing Klebsiella pneumoniae (ESBL-Kp) have been frequently reported worldwide. We have no information on such problems in Bahia, Brazil. OBJECTIVES: Evaluate the risk factors for nosocomial infections caused by ESBL-Kp, in a tertiary hospital, in Bahia, Brazil. MATERIAL AND METHODS: We evaluated all reported cases of nosocomial infections caused by ESBL-Kp in a private, tertiary hospital, in Salvador, Brazil, from 2000 through 2004. We compared patients with a diagnosis of ESBL-Kp (cases) and patients infected by non-ESBL producing K. pneumoniae (controls). Mean age, underlying disease, and frequency of invasive procedures were compared between the two groups. History of previous use of... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Nosocomial infections; ESBL; Klebsiella pneumoniae; Bacterial resistance. |
Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000300007 |
| |
|
|
Pedral-Sampaio,Diana Brasil; Netto,Eduardo Martins; Brites,Carlos; Bandeira,Antonio Carlos; Guerra,Conceição; Barberin,Maria Goreth; Badaró,Roberto. |
It has been postulated that deficient or incomplete clinical and/or microbiological response to tuberculosis treatment is associated with cell-mediated immunological dysfunction involving monocytes and macrophages. A phase 2 safety trial was conducted by treating patients with either recombinant human granulocyte-macrophage colony-stimulating factor (rhu-GM-CSF) or a placebo, both in combination with anti-tuberculosis chemotherapy. Thirty-one patients with documented pulmonary tuberculosis were treated with rifampin/isoniazid for six months, plus pyrazinamide for the first two months. At the beginning of treatment, rhu-GM-CSF (125µg/M²) was randomly assigned to 16 patients and injected subcutaneously twice weekly for four weeks; the other 15 patients... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Tuberculosis; GM-CSF; Treatment. |
Ano: 2003 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000400004 |
| |
|
|
|